Cipla gets EIR from USFDA for Invagen manufacturing facility


NEW DELHI, Jan 28: Homegrown pharma major Cipla on Tuesday said it has received a report from the US health regulator indicating closure of the inspection at its US Invagen manufacturing facility.

“Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection,” Cipla said in a filing to BSE.



Please enter your comment!
Please enter your name here